Building on Sipuleucel-T for Immunologic Treatment of Castration-Resistant Prostate Cancer

Siegel R. , Naishadham D. , Jemal A. . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1): 10–29.

de Bono J.S. , Logothetis C.J. , Molina A. . Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364(21): 1995–2005.

de Bono J.S. , Oudard S. , Ozguroglu M. . Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376(9747): 1147–1154.

Fizazi K. , Carducci M. , Smith M. . Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377(9768): 813–822.

Parker C. , Heinrich D. , O'Sullivan J.M. . Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Oncol (ASCO Genitourinary Cancers Symposium Annual Abstracts). 2012; 30(suppl 5): 8.

Scher H.I. , Fizazi K. , Saad F. . Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367(13): 1187–1197.

Described in the Exelixis website 11/18/2010 press release (http://exelixis.com/investors-media/press-releases), in reference to Smith D.C. , Spira A. , De Grève J. . Phase 2 study of XL184 in a cohort of patients with castration resistant prostate cancer (CRPC) and measurable soft-tissue disease. Presented at the 22nd Annual EORTC- NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; November 16-19, 2010; Berlin, Germany. Eur J Cancer. 2010; 8(7 suppl): 129. Poster 406.

Kantoff P.W. , Schuetz T.J. , Blumenstein B.A. . Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010; 28(7): 1099–1105.

Hodi F.S. , O'Day S.J. , McDermott D.F. . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8): 711–723.

Higano C.S. , Schellhammer P.F. , Small E.J. . Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009; 115(16): 3670–3679.

Haines A.M. , Larkin S.E. , Richardson A.P. . A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry. Br J Cancer. 1989; 60(6): 887–892.

Valone F.H. , Small E. , MacKenzie M. . Dendritic cell-based treatment of cancer: closing in on a cellular therapy. Cancer J. 2001; 7(suppl 2): S53–S61.

Laus R. , Yang D.M. , Ruegg C.L. . Dendritic cell immunotherapy of prostate cancer: preclinical models and early clinical experience. Cancer Res Ther Cont. 2001; 11: 1–10.

Sheikh N.A. , Jones L.A. . CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol Immunother. 2008; 57(9): 1381–1390.

Kantoff P.W. , Higano C.S. , Shore N.D. . Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363(5): 411–422.

Drake C.G. . Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol. 2010; 10(8): 580–593.

Sheng K.C. , Wright M.D. , Apostolopoulos V. . Inflammatory mediators hold the key to dendritic cell suppression and tumor progression. Curr Med Chem. 2011; 18(36): 5507–5518.

Sato T. , Terai M. , Tamura Y. . Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res. 2011; 51(2-3): 170–182.

Nagaraj S. , Schrum A.G. , Cho H.I. . Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol. 2010; 184(6): 3106–3116.

Kusmartsev S. , Gabrilovich D.I. . Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev. 2006; 25(3): 323–331.

Poschke I. , Mao Y. , Adamson L. . Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. Cancer Immunol Immunother. 2012; 61(6): 827–838.

Burch P.A. , Breen J.K. , Buckner J.C. . Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res. 2000; 6(6): 2175–2182.

Provenge® (sipuleucel-T) [Prescribing Information]. Dendreon Corporation, Seattle, WA; June 2011. http://www.provenge.com/pdf/prescribing-information.pdf. Accessed October 1, 2012.

Sheikh N.A. , Petrylak D. , Kantoff P.W. . Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother. 2012 Aug 3. Epub ahead of print.

Small E.J. , Schellhammer P.F. , Higano C.S. . Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006; 24(19): 3089–3094.

Frohlich M.W. . Sipuleucel-T for the treatment of advanced prostate cancer. Semin Oncol. 2012; 39(3): 245–252.

Gomella L.G. , Nabhan C. , Whitmore J.B. . Post-progression treatment with APC8015F may have prolonged survival of subjects in the control arm of sipuleucel-T phase III studies. J Clin Oncol (ASCO Annual Meeting Abstracts). 2011; 29(suppl): 4534.

Hall S.J. , Klotz L. , Pantuck A.J. . Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. J Urol. 2011; 186(3): 877–881.

A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer (PROCEED). http://www.clinicaltrials.gov/ct2/show/NCT01306890. Accessed October 1, 2012.

Huber M.L. , Haynes L. , Parker C. . Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst. 2012; 104(4): 273–279.

Gulley J.L. , Leitman S.F. , Dahut W. . Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst. 2012; 104(14): 1106.

Drake C.G. . Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst. 2012; 104(18): 1422.

Kantoff P.W. , Higano C.S. , Small E.J. . Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst. 2012; 104(14): 1107–1109.

Fan C. , George B. , Bross P. . Clinical Review: Sipuleucel-T. April 28, 2010. http://www.fda.gov/downloads/biologicsbloodvaccines/cellulargenetherapyproducts/approvedproducts/ucm214540.pdf. Accessed October 1, 2012.

Dendreon Corporation. Dendreon ON Call. https://www.dendreononcall.com/Registration/Registration.aspx. Accessed November 19, 2012.

McGee D.C. , Gould M.K. . Preventing complications of central venous catheterization. N Engl J Med. 2003; 348(12): 1123–1133.

Beer T.M. , Bernstein G.T. , Corman J.M. . Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res. 2011; 17(13): 4558–4567.

McNeel D.G. , Lin D.W. , Gardner T. . Correlation of increased eosinophil count following sipuleucel-T treatment with outcome in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol (ASCO Annual Meeting Abstracts). 2012; 30(suppl): 4650.

Sims R.B. , Wener M.H. , dela Rosa C.P. . Increased gamma globulin following immunotherapy with sipuleucel-T is associated with antigen-specific antibody responses. Blood. (ASH Annual Meeting Abstracts). 2010; 116: 1738.

Madan R.A. , Gulley J.L. , Fojo T. . Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist. 2010; 15(9): 969–975.

Gulley J.L. , Drake C.G. . Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res. 2011; 17(12): 3884–3891.

Small E.J. , Higano C.S. , Kantoff P.W. . Time to disease-related pain after sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): results from three randomized phase III trials. J Clin Oncol (ASCO Annual Meeting Abstracts). 2011; 29(suppl): 4661.

Chodak G. , Schellhammer P.F. , Whitmore J.B. . Overall survival (OS) benefit with sipuleucel-T by baseline PSA: an exploratory analysis from the phase III IMPACT trial. J Clin Oncol (ASCO Annual Meeting Abstracts). 2012; 30(suppl): 4648.

Sheikh N.A. , Small E.J. , Quinn D.I. . Sipuleucel-T product characterization across different disease states of prostate cancer. J Clin Oncol (ASCO Annual Meeting Abstracts). 2012; 30(suppl 5): 42.

Aragon-Ching J.B. , Williams K.M. , Gulley J.L. . Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci. 2007; 12: 4957–4971.

Kanda N. , Watanabe S. . Ketoconazole suppresses interleukin-4 plus anti-CD40–induced IgE class switching in surface IgE negative B cells from patients with atopic dermatitis. J Invest Dermatol. 2002; 119(3): 590–599.

Beetens J.R. , Loots W. , Somers Y. . Ketoconazole inhibits the biosynthesis of leukotrienes in vitro and in vivo. Biochem Pharmacol. 1986; 35(6): 883–891.

Baroni A. , Ruocco V. , De Paolis P. . Ketoconazole inhibits lipopolysaccharide-induced activation of the nitric oxide synthase gene in the murine macrophage cell line J774. Arch Dermatol Res. 1999; 291(1): 54–58.

Dawson N.A. , Pessis D.A. , McNeel D.G. . Patients treated with sipuleucel-T who had prior docetaxel had positive immune responses and survival benefit. Presented at the 2011 European Multidisciplinary Cancer Congress; September 23-27, 2011; Stockholm, Sweden. Eur J Cancer. 2011; 47(suppl 1): S487–S488. Poster 7012.

Mercader M. , Bodner B.K. , Moser M.T. . T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A. 2001; 98(25): 14565–14570.

Drake C.G. , Doody A.D. , Mihalyo M.A. . Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell. 2005; 7(3): 239–249.

Gannon P.O. , Poisson A.O. , Delvoye N. . Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods. 2009; 348(1-2): 9–17.

Sutherland J.S. , Goldberg G.L. , Hammett M.V. . Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol. 2005; 175(4): 2741–2753.

Koh Y.T. , Gray A. , Higgins S.A. . Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate. 2009; 69(6): 571–584.

Madan R.A. , Gulley J.L. , Schlom J. . Analysis of overall survival in patients with nonetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res. 2008; 14(14): 4526–4531.

Fong L. , Weinberg V.K. , Chan S.E. . Neoadjuvant sipuleucel-T in localized prostate cancer: effects on immune cells within the prostate tumor microenvironment. J Clin Oncol (ASCO Annual Meeting Abstracts). 2012; 30(suppl): 2564.

Finkelstein S.E. , Timmerman R. , McBride W.H. . The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol. 2011; 2011: 439752.

Brode S. , Cooke A. . Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit Rev Immunol. 2008; 28(2): 109–126.

Farsaci B. , Higgins J.P. , Hodge J.W. . Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer. 2012; 130(8): 1948–1959.

Mirza N. , Fishman M. , Fricke I. . All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006; 66(18): 9299–9307.

Nagaraj S. , Schrum A.G. , Cho H.I. . Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol. 2010; 184(6): 3106–3116.

Herber D.L. , Cao W. , Nefedova Y. . Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med. 2010; 16(8): 880–886.

Bogunovic D. , Manches O. , Godefroy E. . TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity. Cancer Res. 2011; 71(16): 5467–5476.

Weber J. . Immune checkpoint proteins: a new therapeutic paradigm for cancer—preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol. 2010; 37(5): 430–439.

Peethambaram P.P. , Melisko M.E. , Rinn K.J. . A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clin Cancer Res. 2009; 15(18): 5937–5944.

Park J.W. , Melisko M.E. , Esserman L.J. . Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER2 overexpressing breast cancer. J Clin Oncol. 2007; 25(24): 3680–3687.

Swietach P. , Hulikova A. , Vaughan-Jones R.D. , Harris A.L. . New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene. 2010; 29(50): 6509–6521.

Stillebroer A.B. , Mulders P.F. , Boerman O.C. . Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol. 2010; 58(1): 75–83.

Finkelstein S.E. , Fishman M. . Clinical opportunities in combining immunotherapy with radiation therapy. Front Oncol. 2012; 2: 169. Epub 2012 November 26.